Company Overview
Picard Medical, Inc. (PMI) serves as a holding company fully owning SynCardia Systems, LLC, a medical technology firm focused on the SynCardia Total Artificial Heart (TAH)—the sole FDA- and Health Canada-approved implantable TAH, with over 2,100 units implanted across 27 countries as a bridge to transplantation for biventricular heart failure patients. The system includes artificial ventricles, external pneumatic drivers for hospital and home use, and drivelines, implanted via standard surgical methods to deliver pulsatile flow. The company's roadmap involves enhancing driver technology, broadening indications to Bridge to Candidacy and long-term use (two years+), expanding globally, and pioneering the fully implantable Emperor TAH as a transplant alternative, with prototypes in testing, animal studies slated for early 2025, and potential FDA approval by 2028. Facing competitors like Carmat's Aeson TAH, BiVACOR's clinical trials, and off-label LVAD combinations, Picard emphasizes its clinical expertise, intellectual property, and advantages in mechanical circulatory support. In 2025, it pursued an NYSE IPO to secure approximately USD 17 million for growth and innovation.
Initial Public Offering
The company launched its IPO on August 29th, 2025, under the ticker PMI and had sold approximately 4,250,000 shares at USD 4.00 share. We had covered this IPO in our ‘Kalkine IPO Report’ on August 18, 2025, and had concluded that this IPO was “Attractive” given it given the financial performance of the company, use of proceeds, and associated risks.
Conclusion
The closing price of $9.60 for Picard Medical, Inc. (NYSE American: PMI) (October 8, 2025) offers IPO investors a 140.00% price surge from the $4.00 IPO price. This realized return is a key factor. However, the company faces deepening financial weaknesses. Despite revenue growth, the net loss increased to $6.72 million, driven by non-cash charges. Crucially, gross profit turned negative, signaling rising costs and financial strain. Given the significant surge from the IPO price and the growing financial risks, investors who participated in the IPO can consider exiting their position at the closing price of $9.60 as on October 08, 2025.
*The reference data in this report has been partly sourced from Refinitiv.
Disclaimer-
This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.
Past performance is not a reliable indicator of future performance.
AU
CA
US
NZ
IND
UK
Please wait processing your request...